KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $4.9 million.

  • TherapeuticsMD's Total Current Liabilities fell 1725.23% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year decrease of 1725.23%. This contributed to the annual value of $5.2 million for FY2024, which is 2462.8% down from last year.
  • TherapeuticsMD's Total Current Liabilities amounted to $4.9 million in Q3 2025, which was down 1725.23% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Total Current Liabilities ranged from a high of $264.8 million in Q1 2022 and a low of $4.7 million during Q2 2025
  • For the 5-year period, TherapeuticsMD's Total Current Liabilities averaged around $64.1 million, with its median value being $14.5 million (2023).
  • As far as peak fluctuations go, TherapeuticsMD's Total Current Liabilities surged by 33214.38% in 2022, and later plummeted by 9269.89% in 2023.
  • TherapeuticsMD's Total Current Liabilities (Quarter) stood at $252.9 million in 2021, then crashed by 81.48% to $46.8 million in 2022, then crashed by 85.37% to $6.9 million in 2023, then decreased by 24.63% to $5.2 million in 2024, then fell by 4.28% to $4.9 million in 2025.
  • Its Total Current Liabilities was $4.9 million in Q3 2025, compared to $4.7 million in Q2 2025 and $4.7 million in Q1 2025.